semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hepatitis C, Chronic Patients with a chronic HCV infection (HCV antibodies and HCV RNA positive) Presence of a HCV genotype 1 infection Presence of a compensated liver disease satisfying following hematological and biochemical minimum Hemoglobin value >= 13 g/dl in men, >= 12 g/dl in women Leukocytes >= 3.000/mm3 or neutrophile granulocytes > 1.500/mm3 Thrombocytes > 80.000/mm3 Total bilirubin in the normal range Albumin in the normal range Serum creatinine in the normal range THS in the normal range of an autoimmune hepatitis  Age < 18 years, > 70 years Previous treatment of hepatitis c with (Peg)Interferon alfa or (Peg)Interferon alfa/Ribavirin Patients with organ transplantations other than cornea or hair Infection with HCV genotype 2,3,4,5 or 6 Pregnant or nursing women Any other reason for the liver disease than chronic hepatitis C Suspected hypersensitivity to Interferon, Peginterferon or Ribavirin Participation in a clinical trial or treatment with an investigational product 30 days before in this study Patients with any kind of hemoglobinopathy Documented liver disease in advanced state Liver cirrhosis Child B and C
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  CHRONIC HEPATITIS B Confirmed active liver disease due to Hepatitis B virus Patients must have adequate blood & liver functions Female patients of child-bearing potential must be non pregnant and willing to abstain from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication or be willing to consistently and correctly use an acceptable method of birth control Patients who have serious concurrent illnesses other than hepatitis B like cancer, severe heart disease, uncontrolled diabetes mellitus or AIDS will not be eligible  Persons allergic to lamivudine or suffering from hepatitis C, D or E infection or taking alcohol will not be eligible
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coinfection With Hepatitis B Virus and Hepatitis C Virus Monoinfection With Hepatitis C Virus Patients who were randomized, treated and returned for follow up in the ML17862 protocol will be eligible for in this protocol  Patients unwilling to provide informed consent or abide by the requirements of the study Patients who have already initiated anti-HCV or HBV treatment, approved or investigational since completion of the original protocol
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infection Completed AVX-201 protocol, Plasma HIV RNA <5000 copies/ml, CD4 cells >50  Pregnant or breastfeeding females, withdrawal from AVX-201
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Cirrhosis To fulfill for study entry, the patient must be 18 years of age or older have detectable HCV RNA require orthotopic liver transplantation for chronic hepatitis C induced cirrhosis or require renal transplantation for end-stage kidney disease have a MELD score greater than 18 (for liver transplant patients) or have an otherwise high probability of receiving a liver or kidney transplant within six months of enrollment based on assessment by the clinical transplant team at each hospital be able/willing to travel to the collaborating center for blood sampling prior to liver or kidney transplantation, and at 2, 3, 4, 5, 6, 8, 12, 16, 24 weeks after transplantation and then bi-annually until the end of the study at 5 years be willing to have study-related liver biopsies at 3 months, and then 1, 3 and 5 years after transplantation provide informed consent  To fulfill for study entry, the patient must NOT be HIV or Hepatitis B virus (HBsAg) positive receive a liver graft from an anti-HCV antibody positive or HBV core positive donor have other forms of liver disease including primary biliary cirrhosis, autoimmune hepatitis, hemochromatosis and Wilson's Disease have hepatocellular carcinoma if any single lesion is 5 cm. or more or if there are 3 or more lesions exceeding 3 cm be on immunomodulatory medications such as corticosteroids within four weeks of collection of blood for pre-transplant baseline laboratory testing have been diagnosed with any hereditary or acquired immunodeficiency state prior to liver or kidney transplantation
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Hepatitis B Infection Chronic HBV infection, with either HBeAg-positive (HBeAb-negative) or HBeAg-negative (HBeAb-positive) disease Black/African American Race and/or Hispanic ethnicity Nucleoside/tide-naive Males or females ≥ 16 years of age (or minimum age required in a given country) Compensated liver function ALT of 1.3 to 10 x upper limit of normal (ULN) No Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV)  Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 weeks after study medication has been discontinued Women who are pregnant or breastfeeding Women with a positive pregnancy test on enrollment or prior to study drug administration Evidence of decompensated cirrhosis including but not limited to: variceal bleeding; hepatic encephalopathy; or ascites requiring management with diuretics or paracentesis Recent history of pancreatitis (resolution of any recent pancreatitis must be documented by normal lipase at least 12 weeks prior to the first dose of study medication) Currently abusing illegal drugs or alcohol sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications Serum creatinine > 1.5 mg/dL Hemoglobin < 10.0 g/dL Platelet count < 70,000/mm3
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Non-Alcoholic Fatty Liver Disease Subjects will be eligible for enrollment in this study if they meet the following Males or females; age at least 18 years at screening Abnormal ALT > 65 IU/L (ie, approximately 1.5 x upper limit of normal) Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of silymarin. Females of childbearing potential must be using two reliable forms of effective contraception during the study (while on drug and during follow-up) Hepatitis C virus (HCV) patients Previous treatment with any interferon-based therapy without sustained virological response Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of screening and after the end of therapy No antiviral therapy for at least 6 months prior to screening visit Nonalcoholic fatty liver disease (NAFLD) patients Liver biopsy compatible with NAFLD within 3 years of screening  Subjects with any of the following will not be eligible for participation Use of silymarin or other milk thistle preparations within 30 days of screening Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, within 30 days of screening. A multivitamin at standard doses will be allowed Allergy/sensitivity to milk thistle or its preparations Use of silymarin or other antioxidants (as above) during the screening period Use of warfarin, metronidazole or chronic use of acetaminophen greater than two gram per day Previous liver biopsy that demonstrated presence of cirrhosis Previous liver biopsy that demonstrated greater than or equal to 15% steatosis or evidence of steatohepatitis for HCV cohort Positive test for anti-HIV or HBsAg within 3 years of screening Positive urine drug screen for drugs of abuse at screening
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis HCV genotype 4 Patients that have not previously received peginterferon  Patients unable to take oral medications Use of ribavirin within 30 days prior to enrollment Females who are either pregnant, breast-feeding or not using birth control and are sexually active Any investigational drug therapy within 30 days prior to enrollment other than through Romark study number RM01-3027 Patients with other causes of liver disease Transplant recipients receiving immune suppression therapy Patient co-infected with human immunodeficiency virus, hepatitis A virus, hepatitis B virus, or hepatitis D virus based on enzyme immunoassay Patients with decompensated cirrhosis, thrombocytopenia (platelet count <80,000), neutropenia, history of variceal bleeding, ascites, hepatic encephalopathy or CTP scores >6 Patients with history of alcoholism (unless abstinent for 2 years) or with an alcohol consumption of >20 grams per day Patients who are clinically unstable
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥ 18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis  Patients unable to take oral medications Use of interferon alpha within 90 days or ribavirin within 30 days prior to enrollment Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active Any investigational drug therapy within 30 days prior to enrollment Patients with other causes of liver disease Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus based on enzyme immunoassay Patients with history of alcoholism or with an alcohol consumption of >40 grams per day Patients who are clinically unstable Patients with any concomitant condition that, in the opinion of the investigator would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis HCV genotype 4  Patients who have previously failed to respond to ≥12 weeks of peginterferon-ribavirin combination therapy Females who are either pregnant, breast-feeding or not using birth control and are sexually active Males whose female partners are pregnant Patients with other causes of liver disease (i.e., autoimmune hepatitis, decompensated liver disease) Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus Patients with a history of alcoholism or with an alcohol consumption of >40 grams per day Patients with hemoglobinopathies (i.e., thalassemia major, sickle-cell anemia) Patients with any concomitant condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed History of hypersensitivity or intolerance to any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectionable solution or ribavirin tablets
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections AIDS Age > 17 years Informed consent signed Effective ongoing treatment (HIV-RNA < 50 copies/ml). Treatment must be based on any triple drug therapy. Patients must be on the same steady therapy for at least 3 months Current CD4 cell count above 600 cells/mcL and nadir of CD4 cell count > 200 cells/mcL  Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviors Any ongoing grade 4 (WHO) AE or laboratory abnormality with the of cholesterol, triglycerides for which a grade 3 (AHA) level will be considered an Previous diagnosis of AIDS Patients with HBV coinfection on active anti-HIV treatment with either lamivudine and/or tenofovir
Patient description: The patient is a 55-year-old man diagnosed with HCV 2 years ago and the recent coinfection with HBV. His past medical history is non-significant. He is on IFN, RBV and direct antiviral drugs for the past 6 months. The patient takes no other medications. His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 14.0-999.0,  Unspecified Adult Solid Tumor, Protocol Specific Histologically or cytologically confirmed malignant solid tumor Refractory disease for which curative or palliative measures have failed or for which there is no known superior treatment No colorectal cancer or melanoma Measurable OR nonmeasurable disease Normotensive (blood pressure [BP] ≤ 140/90 mm Hg) meeting 1 of the following No more than 2 attempted measurement sessions for which the documented mean systolic BP is ≤ 140 mm Hg and the diastolic BP is ≤ 90 mm Hg At least 30 attempted measurement sessions for which the documented mean systolic BP is ≤ 135 mm HG and the diastolic BP is ≤ 85 mm Hg Brain metastases allowed provided the following are met Stable neurologic status for ≥ 2 weeks after completion of definitive local therapy (surgery or radiotherapy) No neurologic dysfunction that would confound the evaluation of neurologic and other adverse events